Abstract
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.
Keywords: Angiogenesis, antiangiogenesis, bortezomib, lenalinomide, multiple myeloma, thalidomide, thyrosine kinase inhibitors, zoledronic acid, chorioallantoic membrane, Monoclonal gammopathy of undetermined significance, Platelet-derived growth factor receptor, Hypoxia inducible factor 1 alpha, chorioallantoic membrane.
Current Cancer Drug Targets
Title:Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Volume: 12 Issue: 7
Author(s): Domenico Ribatti, Giuseppe Mangialardi and Angelo Vacca
Affiliation:
Keywords: Angiogenesis, antiangiogenesis, bortezomib, lenalinomide, multiple myeloma, thalidomide, thyrosine kinase inhibitors, zoledronic acid, chorioallantoic membrane, Monoclonal gammopathy of undetermined significance, Platelet-derived growth factor receptor, Hypoxia inducible factor 1 alpha, chorioallantoic membrane.
Abstract: Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.
Export Options
About this article
Cite this article as:
Ribatti Domenico, Mangialardi Giuseppe and Vacca Angelo, Antiangiogenic Therapeutic Approaches in Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429346
DOI https://dx.doi.org/10.2174/156800912802429346 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds
Anti-Cancer Agents in Medicinal Chemistry Recent Trends in the Design, Synthesis and Biological Exploration of β-Lactams
Current Medicinal Chemistry Is Preoperative Endoscopic Biliary Drainage Indicated for Jaundiced Patients with Resectable Pancreatic Cancer?
Current Drug Targets The Anti-tumor Activity and Mechanisms of rLj-RGD3 on Human Laryngeal Squamous Carcinoma Hep2 Cells
Anti-Cancer Agents in Medicinal Chemistry Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Innovative Treatment Approach for Cancer-Related Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Mechanistic Insight of Drug Resistance with Special Focus on Iron in Estrogen Receptor Positive Breast Cancer
Current Pharmaceutical Biotechnology Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer
Current Medicinal Chemistry <sup>89</sup>Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals
Current Topics in Medicinal Chemistry Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design COX-2 and Colorectal Cancer
Current Pharmaceutical Design Modulation of Angiogenesis by Inflammatory Markers and the Role of Matrix Metalloproteinases in an Endothelial Cell/Fibroblast Co-culture System
Current Angiogenesis (Discontinued) Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy